LiverHealthPOD

In this episode of the LiverHealthPOD Paul, John and Will discuss detection of liver fibrosis in the community.

Most people with significant liver scarring have no idea it's happening. No pain, no jaundice, no obvious symptoms — until the disease has already progressed to cirrhosis. In this episode, we explore why detecting liver fibrosis earlier — and closer to home — is one of the most important frontiers in liver health today, and what a painless, non-invasive scan is revealing about the hidden burden of liver disease in our communities.

In this episode of the LiverHealthPOD John, Will and Paul discuss new developments in Hepatitis B.

Hepatitis B affects over 300 million people worldwide and remains the leading cause of liver cancer globally — yet for decades, treatment options have been limited to viral suppression rather than cure. In this episode we break down the exciting wave of new therapies that are changing what's possible for people living with chronic hepatitis B.

If you like the Podcast don't forget to like and subscribe and send us an email with your stories to LiverHealthPOD.

"The 'D' in MASLD — Does It Belong?"

Everyone's talking about MASLD — but are we all agreeing on what it actually is? In this episode, we dive deep into one of hepatology's most hotly debated questions: does metabolic dysfunction-associated steatotic liver disease truly qualify as a disease, or is it a spectrum, a risk factor, or simply a label we've slapped on a very complicated process?

We unpack the very real clinical consequences of how we define this condition.

Whether you're a clinician, a researcher, or someone navigating a MASLD diagnosis yourself, this one will challenge how you think about the liver — and the language we use to talk about it.

🎙️ Got a question or a hot take? We want to hear from you for our Mailbag Segment! Send your thoughts, questions, and controversial opinions to [email protected] and you might just hear yourself featured on the next episode.

Subscribe, rate, and share liverHealthPOD — because your liver deserves the conversation.

In this episode ,Will, Paul and John discuss medications for Alcohol use disorder (AUD) . In this episode, we unpack the evidence-based pharmacotherapies that support recovery, including Naltrexone, Acamprosate, and Disulfiram and more.

This is a practical, stigma-aware conversation focused on improving outcomes—because effective treatment for alcohol use disorder should be accessible and evidence-based.

Don't forget to leave a rating so others can find us and send any questions to [email protected]

In this episode of the LiverHealthPOD John, Will and Paul discuss "Lean MAFLD". These patients may not fit the typical metabolic stereotype, but they can still progress to fibrosis and cirrhosis. which challenges the outdated assumption that fatty liver disease is simply a consequence of obesity.

People with a “normal” BMI can still develop significant hepatic steatosis and inflammation, often driven by a combination of genetic susceptibility, visceral adiposity, insulin resistance, and environmental factors.

Find out more in this episode.

Don't forget to leave us a 5 star rating and send us a message of questions to [email protected]

In this episode of the LiverHealthPOD, John, will and Paul

discuss new breakthrough treatments in PBC

For decades, treatment for primary biliary cholangitis (PBC) centred on ursodeoxycholic acid (UDCA or "Urso"). But the therapeutic landscape is rapidly evolving.

In this episode of LiverHealthPOD, we explore the emerging wave of treatments transforming care for PBC.

What do these therapies mean for patients who don’t respond adequately to standard treatment? How do clinicians decide when to escalate therapy? And what might the future hold for disease modification in PBC?

Join us as we unpack the latest science and clinical advances shaping the next chapter in PBC care.

Don't forget to send through any questions (about the liver) to [email protected]

in this episode of the LiverealthPOD, Will, John and Paul discuss CBD oil and the lvier.

CBD oil has exploded in popularity—marketed for everything from anxiety and insomnia to chronic pain and inflammation. But what does it actually do to the liver?

In this episode we unpack the science behind cannabidiol (CBD). We explore how CBD is metabolised by the liver, what the evidence says about elevated liver enzymes, and whether there are real risks of liver injury.

we tackle what clinicians and patients should know before using CBD products.

Join us as we separate evidence from hype.

Don't forget to like and subscribe and send us any questions to [email protected]

One of the most common questions we get asked in the LiverHealthPod is what about Creatine? In this episode Paul, John and Will - three liver doctors with over 60 years of collective experience in managing liver disease discuss their opinion of Creatine. If you want to hear the evidence tune into this episode of the LiverHealthPOD

Send us an email at [email protected]

In the episode,

Will, Paul and John examine new and emerging data around the impact of diet Sodas and non-nutritive sweeteners on liver health.

Listen in to hear more and don't forget to like and subscribe and send us a message at [email protected]

In the episode,

John, Will and Paul delve deep into a recent study (J Hepatol 2025 Dec;83(6):1256-1265.doi: 10.1016/j.jhep.2025.06.005) on the health effects of calorie restriction and time restriction style of eating on liver fat and weight loss.

Listen in to hear more and don't forget to like and subscribe and send us a message at [email protected]